SIV DNA VACCINES AND MUCOSAL IMMUNITY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 SIV DNA疫苗与粘膜免疫 全球80%以上的艾滋病毒感染传播是通过粘膜途径进行的。疫苗诱导粘膜免疫的能力可能是预防艾滋病毒感染和感染后出现的免疫缺陷综合征所必需的。目前正在开发各种艾滋病疫苗候选者，每一种都有潜在的优点和缺点。DNA疫苗具有吸引人的HIV候选疫苗的特点，DNA疫苗和重组疫苗的组合是艾滋病疫苗开发中受欢迎的方法之一。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SIV DNA vaccines and mucosal immunity More than 80 percent of global transmission of HIV infection occurs via mucosal routes. The ability of vaccines to induce mucosal immunity may be required for protection against HIV infection and the immunodeficiency syndrome that emerges after infection. Various AIDS vaccine candidates are currently under development, each with potential advantages and disadvantages. DNA vaccines have features that make them attractive vaccine candidates for HIV and the combination of DNA vaccination plus recombinant vaccinia is one of the favored approaches in AIDS vaccine development.